Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
18.6(c) 18.4(c) 18.05(c) 18.05(c) 18(c) Last
4 350 085 1 988 807 1 562 916 1 393 036 1 401 827 Volume
+0.54% -1.08% -1.90% 0.00% -0.28% Change
More quotes
Financials ($)
Sales 2017 253 M
EBIT 2017 115 M
Net income 2017 -152 M
Debt 2017 262 M
Yield 2017 -
Sales 2018 261 M
EBIT 2018 114 M
Net income 2018 55,1 M
Debt 2018 155 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 20,46
EV / Sales2017 4,36x
EV / Sales2018 3,81x
Capitalization 842 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products.It operates through the following geographic segments: Asia, the Americas, and Europe.It offers Lubiprostone, which treats... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
01/11 SUCAMPO PHARMACEUTICALS : Wolf Popper LLP Investigates the Proposed Acquisition ..
01/04 MALLINCKRODT : To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
01/03 Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whethe..
01/02 SUCAMPO PHARMACEUTICALS, INC. : Other Events (form 8-K)
01/01 Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceutic..
2017 SUCAMPO PHARMACEUTICALS, INC. Former SEC Attorney Willie Briscoe Investigates..
2017 MALLINCKRODT : to Acquire Sucampo Pharmaceuticals for Approximately $1.2 Billion
2017 SUCAMPO PHARMACEUTICALS, INC. : SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announ..
2017 CORRECTING AND REPLACING INVESTOR AL : Levi & Korsinsky, LLP Notifies Investors ..
2017 SUCAMPO PHARMACEUTICALS, INC. Rigrodsky & Long, P.A. Announces Investigation ..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
SUCAMPO PHARMACEUTICALS - 2015
The bullish trend is not over
BUY
More Strategies
Latest Tweets
01/17Get the latest ratings for $SCON $STRZA $SCMP $TAHO $DVD in your inbox with M.. 
01/16TREND REVERSAL DOWN ALERT: $SCMP SUCAMPO PHARMACEUTICALS ? TradeIdeas via  
01/09BMO Capital "pleased" with Mallinckrodt steps to evolve portfolio:  
01/08Mother Alleges Biotech Firm Stole Data From Her Sick Children #JPM18 $SCMP $M..
10
01/06Sucampo Pharmaceuticals $SCMP Downgraded to “Neutral” at UBS Group  
More tweets
Qtime:71
News from SeekingAlpha
01/08 Synergy Pharmaceuticals' Trulance Enters Its Sophomore Year
01/04 MALLINCKRODT : Recent Insider Buying Sending A Buy Signal?
01/03 YOUR DAILY PHARMA SCOOP : Achaogen Is A Compelling Investment, Protalix Gains On..
01/02 Premarket analyst action - healthcare
01/02 Moody's Downgrade Could Punish Mallinckrodt
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 21,7 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Maureen E. O'Connell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.0.56%842
GILEAD SCIENCES10.30%104 801
REGENERON PHARMACEUTICALS-2.39%39 775
VERTEX PHARMACEUTICALS5.39%39 380
GENMAB11.42%11 532
EXELIXIS, INC.-0.07%8 772